Anthera Pharmaceuticals Inc. (ANTH) Shares Down 1.9%
Shares of Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) fell 1.9% during mid-day trading on Tuesday . The stock traded as low as $3.12 and last traded at $3.13, with a volume of 442,932 shares changing hands. The stock had previously closed at $3.19.
Several brokerages recently issued reports on ANTH. Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, April 25th. Jefferies Group restated a “buy” rating on shares of Anthera Pharmaceuticals in a report on Thursday, June 9th. HC Wainwright began coverage on shares of Anthera Pharmaceuticals in a report on Friday, July 8th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, FBR & Co restated a “hold” rating on shares of Anthera Pharmaceuticals in a report on Monday, June 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $9.58.
The firm’s market cap is $133.39 million. The stock has a 50 day moving average price of $3.22 and a 200 day moving average price of $3.42.
Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.04. Equities research analysts anticipate that Anthera Pharmaceuticals Inc. will post ($1.37) EPS for the current fiscal year.
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.